Connective tissue diseases following silicone breast implantation: where do we stand?

Juliane G Hortolam, Jozélio Freire de Carvalho, Simone Appenzeller
State University of Campinas, Faculty of Medical Science, Department of Medicine, Rheumatology Unit, Campinas/SP, Brazil.

Silicone, which is considered biologically inert, has been used in many different types of medical devices, including tubing; breast, joint and penile implants; artificial heart valves; and intraocular lenses, among others. After a silicone implant is placed, a mild reaction to the foreign body is generally observed, followed by encapsulation (1).

Case reports of women with silicone breast implants and connective tissue disease (CTD), especially scleroderma, began to appear in English-language medical literature in the 1980s. Currently, it is widely believed that there is no association between silicone breast implants and autoimmune disease (1). However, when a patient presents with autoimmune symptoms after silicone breast implantation, the question often arises again.

Although several authors have reported the appearance of CTDs (e.g., scleroderma, Still’s disease, systemic lupus erythematosus (SLE), Sjogren’s Syndrome and dermatomyositis) after silicone breast implantation, several case-control studies do not show such an association. However, there are a few points that deserve attention. Silicone breast implants act as a foreign body, and inflammatory responses to silicone, such as granulomatous skin reactions to injected silicone, synovitis around silicone prosthetic joints and lymphadenopathy proximal to silicone prostheses, have been observed (2,3). Microscopic evidence of silicone has been observed far from the original site (e.g., in the liver), suggesting that a small quantity of silicone particles detaches and migrates through the lymphatic or circulatory system to other organs (1,4–6). They may act as adjuvants and start an inflammatory process in joints or activate the immune system and stimulate the production of autoantibodies (1,2).

The activation of the immune system has been demonstrated by the presence of antibodies to silicone and the presence of autoantibodies in the sera of patients with silicone breast implants. Although several studies have detected increased titers of anti-silicone antibodies, no association with clinical findings has been observed (6-10). Significantly more patients with silicone breast implants present with positive anti-DNA, Sjogren syndrome antigen B (anti-SSB/La) and anticollagen II (6-10). Antibodies and symptoms were more evident in patients who had possessed implants for a longer time period (10).

In conclusion, silicone breast implants may act as a foreign body and elicit autoantibody production. However, thus far, no clear link between the presence of autoantibodies and symptoms has been observed.

**AUTHOR CONTRIBUTIONS**

All authors participated in the preparation and correction of the text.

**REFERENCES**


Email: appenzellersimone@yahoo.com
Tel.: 55 19 3289-1818

Copyright © 2013 CLINICS – This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

No potential conflict of interest was reported.

DOI: 10.6061/clinics/2013(03)E01